Efficacy and safety of schedule-modified oral capecitabine/S-1 as maintenance therapy for stage N3 nasopharyngeal carcinoma after definitive chemoradiotherapy: a multicentre, single-arm phase II clinical trial
Xiang Lin, Linyi Huang, Jifang Zheng, Bingcan Chen, Chaobin Huang, Lisha Chen, Caizhu Pan, Qiaojuan Guo, Shaojun Lin, Jingfeng Zong · 2026
Read Efficacy and safety of schedule-modified oral capecitabine/S-1 as maintenance therapy for stage N3 nasopharyngeal carcinoma after definitive chemoradiotherapy: a multicentre, single-arm phase II clinical trial by Xiang Lin, Linyi Huang, Jifang Zheng, Bingcan Chen, Chaobin Huang, Lisha Chen, Caizhu Pan, Qiaojuan Guo, Shaojun Lin, Jingfeng Zong (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13471540.txt.
Description
Lin and colleagues tested whether a year of oral maintenance chemotherapy after chemoradiation can hold back the most node-advanced form of nasopharyngeal cancer. Their 2026 multicentre phase II trial enrolled 115 patients with stage N3 disease, giving 12 cycles of capecitabine or S-1 tablets on a modified schedule after definitive treatment.
After a median follow-up of 46.2 months, two-year progression-free survival reached 92.0% of patients, with overall survival at 98.3% and distant metastasis-free survival at 92.9% over the same span. Treatment was gentle for chemotherapy: only 7.0% of patients had grade 3 side effects, none reached grade 4 or 5, and 78.3% finished all 12 cycles. The single-arm design means randomized trials must confirm the benefit.
Catalog record
| CREATOR | Xiang Lin, Linyi Huang, Jifang Zheng, Bingcan Chen, Chaobin Huang, Lisha Chen, Caizhu Pan, Qiaojuan Guo, Shaojun Lin, Jingfeng Zong |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |